Navigation Links
Repligen Announces Completion of Patient Enrollment in Phase 2b Clinical Trial of RG2417 for Bipolar Depression
Date:9/30/2010

recruited into this study was 31.3 compared to 30.4 in the Phase 2a study and there has been a high degree of fidelity between the MADRS scores determined by the raters and the patient's self-assessment of depression symptoms during the 8-week treatment period.  To date, there have been no serious adverse events determined to be related to RG2417, which continues to support an advantageous tolerability and safety profile for the drug.

"We are very pleased to have completed the patient enrollment phase of this study," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation.  "We believe that this study has been adequately powered to detect a potential benefit of treatment with RG2417 consistent with our Phase 2a results."

This study was designed to confirm and extend the results of a Phase 2a study in which 6 weeks of treatment with RG2417 improved the symptoms of bipolar depression when compared to placebo as measured by the MADRS.  The positive effect of treatment with RG2417 in the Phase 2a study was primarily observed in patients with a significant history of disease as determined by the number of episodes of mania and depression experienced during their lifetime.  The Phase 2a results demonstrated that RG2417 was safe and well tolerated.

Bipolar disorder, also known as manic depression, is an illness marked by extreme changes in mood, thought, energy and behavior in which a person's mood can alternate between the "poles" of mania and depression.  Bipolar disorder is a chronic illness associated with substantial morbidity and mortality, ranking worldwide behind unipolar depression and alcohol abuse among psychiatric illnesses for related disabilities and overall economic burden of illness.  The lifetime financial burden of bipolar disorder in the United States is about $600,000 per patient, depending on resistance to treatment and persistence of symptoms.  Although several the
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Repligen to Present at the Rodman & Renshaw Annual Global Investment Conference
2. Repligen Announces Conference Call of First Quarter Fiscal Year 2011 Results
3. Repligen Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
4. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
5. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
6. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
7. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
8. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
9. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
10. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
11. Warner Chilcott Announces the Closing of its $500 Million Senior Notes Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... OTTAWA , April 17, 2015 /CNW/ - ... GlaxoSmithKline Inc. (GSK) is voluntarily recalling one lot (lot 710535) ... that two glass pieces had been found in one bottle ... are affected at this time. Clavulin-400 is an ... and older to treat various bacterial infections. Clavulin-400 comes as ...
(Date:4/17/2015)... 2015 Contego Medical, the first and ... platform for angioplasty balloon and stent delivery catheters, ... B financing round led by Hatteras Venture Partners, ... on medical devices, biopharmaceuticals, diagnostics and related opportunities ... Group Partners, Lookout Capital and Medical Mutual. ...
(Date:4/17/2015)...  Regulatory leaders in the pharmaceutical industry continue to ... "21 st Century Cures." This ... by Congress soon and if enacted into law, it ... developed and marketed in the United States ... to consider how the proposed changes could impact their ...
Breaking Medicine Technology:Advisory - Clavulin-400 liquid oral antibiotic: One lot recalled after glass pieces found in one bottle 2Contego Medical Closes $5.6 Million in Series B Funding 2Contego Medical Closes $5.6 Million in Series B Funding 321st Century Cures: A Regulatory Game-Changer for the Pharmaceutical Industry 2
(Date:4/18/2015)... Insuranceautoquote.info has released a new blog post ... . , Clients can review important auto insurance ... environment provides important advantages for clients who need affordable ... do not have coverage for their vehicles can purchase ... or hour. Many agencies offer important discounts and drivers ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 In the ... a couple of changes. , "We had to run ... make needed changes," said Jennifer Ramirez, the PR Director. ... happy to say that we are back on track ... in the process of changing phone systems which has ...
(Date:4/18/2015)... 2015 PHOENIX, ARIZONA – In March, ... 11 other secure destruction professionals across the United States, ... He will now display “CSDS” as a professional title ... the National Association of Information Destruction 2015 Annual Conference ... Texas. Of the 20 people who took the exam, ...
(Date:4/17/2015)... WA (PRWEB) April 17, 2015 ERGO-Pedic ... cushions is introducing two new products to help a ... low back pain relief are the second most common ... our first product, designed specifically to help relieve sitting ... Comfort Cushion, and thousands of happy customers later, we ...
(Date:4/17/2015)... From the day Dr. Todd Phillips founded ... organization has empowered young people to create meaningful change in ... fresh water and the Gospel to all of Liberia by ... 17 and 27, students, faculty and staff raised $21,000 through ... water and the Good News of Jesus. , During ...
Breaking Medicine News(10 mins):Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:TheBeautyPlace.com Temporary Number Available 2Health News:Seat Cushion Company Credits Customer Driven Design For Two New Products 2Health News:The Last Well and Liberty U’s TEN Initiative raises $21,000 to Bring Fresh Water & The Gospel to 7,000 Liberians 2
... the Sheikh Zayed Institute for Pediatric Surgical Innovation ... drug that has shown early promise as an option for ... fight off bacterial infections, particularly sepsis. The study, ... Anesthesiology , sheds new light on the role of ...
... ROCHESTER, Minn. -- Global Bridges, a healthcare alliance for ... regional partner, King Hussein Cancer Center (KHCC) in Amman, ... care providers in the Eastern Mediterranean Region (EMRO) on ... training, scheduled for April 27-28 at KHCC, will engage ...
... Rice University bioengineering students in collaboration with the Texas ... chances to arrhythmia victims headed toward cardiac arrest. ... seniors created a unique pad system for automated external ... heart back into a proper rhythm in an emergency. ...
... to increase despite the use of sunscreen and ... prevent melanoma lesion formation, according to Penn State ... melanoma incidence suggests that additional preventive approaches are ... Robertson, Ph.D., professor of pharmacology, pathology, dermatology and ...
... 26, 2011) A study performed by University of ... in treating Ureaplasma-colonized or infected premature infants to prevent ... Pulmonology, showed subjects colonized or infected with the Ureaplasma ... time in the azithromycin-treated group, compared to 94 percent ...
... Reporter , MONDAY, April 25 (HealthDay News) -- The ... of life for people suffering from heart failure, Harvard ... balance and weight-shifting, breathing techniques and focused internal awareness. ... a number of medical conditions, including hypertension (high blood ...
Cached Medicine News:Health News:Study: Resiniferatoxin may increase sepsis-related mortality 2Health News:Health-care alliance for tobacco dependence treatment launches training in the Middle East 2Health News:Unique AED pads give hearts a second chance 2Health News:Topical treatment may prevent melanoma 2Health News:Antibiotic may prove beneficial to preterm infant lung health 2Health News:Tai Chi May Help Heart Failure Patients 2Health News:Tai Chi May Help Heart Failure Patients 3
Lumenis 950 Slit Lamp Zeiss-style diagnostic slit lamp biomicroscope with parallel optics and offering a choice of automatic or fixed eye safety filters for multiple wavelengths....
... Selecta Duo Adding ... Selecta platform creates the Selecta ... 532 nm Photocoagulator combination laser ... procedures involving both the anterior ...
... CS Catheter Delivery System is an ... the placement of permanent leads during ... Catheter Delivery System is made from ... and softness, plus high radial strength ...
... Durability for Excellent Access. Access ... challenging cases. PT² wires combine ... linear elastic nitinol distal core ... tip. This provides excellent access ...
Medicine Products: